Using mixed reality to locate lung nodules before surgery

Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial

Not applicable Interventional Shanghai Chest Hospital · NCT05715996

This study is testing if using mixed reality technology can help doctors find lung nodules more accurately before surgery in patients needing treatment for lung cancer.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment74 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorShanghai Chest Hospital Academic / other
Locations1 site (Shanghai, Shanghai)
Trial IDNCT05715996 on ClinicalTrials.gov

What this trial studies

This clinical trial explores the use of mixed reality technology to improve the localization of solitary pulmonary nodules prior to surgical intervention. By integrating augmented reality into the preoperative process, the study aims to enhance the accuracy of lung nodule localization compared to traditional CT-guided methods. The trial will involve patients who require sub-lobectomy for lung cancer, assessing the effectiveness and efficiency of this innovative approach. Participants will be randomized to receive either the mixed reality-guided localization or the standard method.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with solitary pulmonary nodules measuring 2 cm or less, who require localization for sub-lobectomy.

Not a fit: Patients with multiple lung nodules or those whose nodules are located in the scapular region may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more precise surgical interventions and improved outcomes for patients with lung cancer.

How similar studies have performed: While the use of augmented reality in surgical settings is emerging, this specific application for lung nodule localization is relatively novel and has not been extensively tested in prior studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female ≥ 18years of age;
2. There was no distant metastasis in preoperative clinical evaluation;
3. The attending physician evaluated and confirmed the need for lung nodule localization and sub-lobectomy;
4. Target lung nodule diameter ≤ 2cm
5. The inner edge of the target node is at least 2 cm from the pulmonary artery or pulmonary vein
6. preoperative ECOG physical state score 0/1;
7. Volunteer to participate in the study and sign the informed consent form.

Exclusion Criteria:

1. More than two lung nodules need to be removed at the same time.
2. The target node is located in the scapular region. Because percutaneous localization is obstructed by the scapula, percutaneous localization of pulmonary nodules is not suitable for such patients.
3. The patient has uncontrollable mental illness and cannot make subjective assessment.
4. After being selected, severe complications (unable to tolerate surgery or anesthesia) occurred before operation are not suitable or the treatment plan of the study cannot be implemented as planned;
5. After being selected, the patient's condition changes and needs to be changed from elective surgery to emergency surgery after being confirmed by the competent doctor;
6. At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.

Where this trial is running

Shanghai, Shanghai

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Lung Cancermixed realityLocalizationsublobectomy
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.